$330,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act"
You can find more data on corporate lobbying on Quiver Quantitative.
HIMS Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
HIMS Insider Trading Activity
HIMS insiders have traded $HIMS stock on the open market 53 times in the past 6 months. Of those trades, 0 have been purchases and 53 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 17 sales selling 1,076,432 shares for an estimated $53,976,385.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 12 sales selling 364,347 shares for an estimated $19,158,373.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 3 sales selling 80,042 shares for an estimated $4,088,809.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 8 sales selling 61,499 shares for an estimated $3,398,164.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 9 sales selling 23,531 shares for an estimated $1,166,808.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 16,821 shares for an estimated $733,472.
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HIMS Hedge Fund Activity
We have seen 294 institutional investors add shares of HIMS stock to their portfolio, and 255 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 15,045,710 shares (+549.0%) to their portfolio in Q3 2025, for an estimated $853,392,671
- SRS INVESTMENT MANAGEMENT, LLC removed 4,000,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $226,880,000
- TIDAL INVESTMENTS LLC added 2,707,111 shares (+1779.6%) to their portfolio in Q3 2025, for an estimated $153,547,335
- FARALLON CAPITAL MANAGEMENT LLC added 2,533,271 shares (+30.8%) to their portfolio in Q3 2025, for an estimated $143,687,131
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,504,252 shares (+444.1%) to their portfolio in Q3 2025, for an estimated $142,041,173
- RENAISSANCE TECHNOLOGIES LLC added 2,227,400 shares (+32.4%) to their portfolio in Q3 2025, for an estimated $126,338,128
- D. E. SHAW & CO., INC. removed 1,886,971 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $107,028,995
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HIMS Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/04/2025
- B of A Securities issued a "Underperform" rating on 11/04/2025
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for HIMS, check out Quiver Quantitative's $HIMS forecast page.
HIMS Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 6 analysts offer price targets for $HIMS in the last 6 months, with a median target of $42.5.
Here are some recent targets:
- Mark Mahaney from Evercore ISI Group set a target price of $33.0 on 01/12/2026
- Glen Santangelo from Barclays set a target price of $48.0 on 12/09/2025
- David Larsen from BTIG set a target price of $85.0 on 11/04/2025
- Allen Lutz from B of A Securities set a target price of $32.0 on 11/04/2025
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
